Subject Index

A
Acute Myeloid Leukaemia 30
Adenosine 49
5-Aminoimidazole-4-Carabaxamide (AIC) 103
AMSA 53
Analogue 140
ANLL in Elderly Patients 89
Antiemetic 61
Antiproliferation Activity 75
Ara-C 89
– Metabolism 30

B
Biliary Secretion 26
Bleomycin 22
– Late Effects 6
Breast Cancer Response 124
Bruceantin 169

C
Cancer Pain 71
Chemotherapy 148
Childhood Tumours 53
cis-Platin 120, 140, 179
cis-Platinum 36
Clinical Studies 140
Colorectal Cancer 17
Combined Therapy 17
Cyclophosphamide 26

D
Daunorubicin Metabolism 45
Deoxyadenosine 49
Deoxycoformycin 49
Doxorubicin 93
– DNA Complex 93
DTIC 103

E
Estrogen Receptor 124

F
5-FU 173

G
Growth Characteristics and Curability 1

H
High Dose Methotrexate 156
Hypomagnesaemia 179

I
Intensive Chemotherapy 127
Interferon 75, 97
– Phase I Study 97
Isolated Perfusion 103

J
JM 8 140

K
Kinetics 57

L
Levonantradol 61
Liver Metastasis 17
Lymphocyte Colonies 49

M
Melphalan 57
Mesnum Ifosfamide Toxicity 81
Methotrexate 161, 165
– in Plasma and Erythrocytes 110
Misonidazole Vaginal Administration 110
Murine Tumors and Human Mammary Carcinoma 134
Myeloma 57

N
Nitrosourea 134
Non-Histone Proteins 36

O
O,p'-DDD Therapy 85
Oral and Intramuscular Medroxyprogesterone Acetate 122

P
Pharmacokinetics 26, 103, 156, 165, 173
– of Erythrocyte Methotrexate 65
Pharmacology 22
Phase II Colon Cancer 41
Plasma Concentration 85
Polysorbate 80
Prednimustine in ANLL 10
Pt Complexes Clearances 13

R
Radioimmunoassay 22
Ridway Osteosarcoma 148

S
Salmon Calcitonin 71
Small Cell Anaplastic Lung Carcinoma 1
Smouldering Leukemia 10
Solid Tumours 127
Squamous Cell Carcinoma 156

T
TA-077 134
6-Tg 89
Timing and Methotrexate Toxicity 110
Tissue Concentration 85

V
Vincristine and Prednimustine 89
Vindesine 41